Topical application of valrubicin has a beneficial effect on developing skin tumors

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1483-1490

  Andersen, Stine M ^a   Rosada, Cecilia ^a   Dagnaes Hansen, Frederik ^b   Laugesen, Ina G ^a   de Darkó, Elisabeth ^c   Dam, Tomas N ^d   Stenderup, Karin ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Valderm ApS   (Denmark)

^d ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ACTIN; CASPASE; CYCLINE; CYTOKERATIN 18; DOXORUBICIN; N TRIFLUOROACETYLDOXORUBICIN; PROTEIN BAX; PROTEIN BCL 2; VALRUBICIN;

ACTINIC KERATOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; CREAM; CYTOSTASIS; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; HUMANS; KERATINOCYTES; KERATOSIS, ACTINIC; MICE; PAPILLOMA; SKIN; SKIN NEOPLASMS;

EID: 77955380651     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq122     Document Type: Article

References (47)

1. Onrust,S.V. et al. (1999) Valrubicin. Drugs Aging, 15, 69-75.
2. Sweatman,T.W. et al. (1991) Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study. Cancer Chemother. Pharmacol., 28, 1-6.
3. Wang,J.J. et al. (1971) Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer, 28, 837-843.
4. Israel,M. et al. (1985) Adriamycin analogues. rationale, synthesis, and preliminary antitumor evaluation of highly active DNA-nonbinding N-(trifluoroacetyl)adriamycin 14-O-hemiester derivatives. J. Med. Chem., 28, 1223-1228.
5. Rosada,C. et al. (2009) Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. J. Invest. Dermatol, 130, 455-463.
6. Fuchs,A. et al. (2007) The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol. Surg., 33, 1099-1101.
7. Miller,D.L. et al. (1994) Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol., 30, 774-778.
8. Szeimies,R.M. et al. (2005) Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma. Hautarzt, 56, 430-440.
9. Boutwell,R.K. et al. (1982) Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. Carcinog. Compr. Surv., 7,1-12.
10. Moore,R.J. et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 5, 828-831.
11. Kitajima,Y. et al. (1988) Biphasic effects of 12-O-tetradecanoylphorbol-13-acetate on the cell morphology of low calcium-grown human epidermal carcinoma cells: involvement of translocation and down regulation of protein kinase C. Cancer Res., 48, 964-970.
12. Kondo,S. et al. (1981) Establishment of a cell line of human skin squamous cell carcinoma in vitro. Br. J. Dermatol., 105, 125-132.
13. Kalra,N. et al. (2008) Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol. Appl. Pharmacol., 226, 30-37.
14. Kalra,N. et al. (2008) Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci., 82, 348-358.
15. Boukamp,P. et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol., 106, 761-771.
16. Kragballe,K. et al. (1985) Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br. J. Dermatol., 113, 43-52.
17. Han,S.S. et al. (2001) Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett., 164, 119-126.
18. Rosette,C. et al. (1995) Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B. J. Cell Biol., 128, 1111-1119.
19. Silber,R. et al. (1987) Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase 2. NCI Monogr., 111-115.
20. Krishan,A. et al. (1981) Comparative effects of adriamycin and N-trifluoroacetyladriamycin-14-valerate on cell kinetics, chromosomal damage, and macromolecular synthesis in vitro. Cancer Res., 41, 2745-2750.
21. Dantchev,D. et al. (1984) Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs. Biomed. Pharmacother., 38, 322-328.
22. Krishan,A. et al. (1976) Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Res., 36, 2108-2109.
23. Schwartz,H.S. et al. (1981) DNA damage by anthracycline drugs in human leukemia cells. Cancer Lett., 13, 309-313.
24. Raz,A. (1982) B16 melanoma cell variants: irreversible inhibition of growth and induction of morphologic differentiation by anthracycline antibiotics. J. Natl Cancer Inst., 68, 629-638.
25. Wani,M.K. et al. (2000) Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope, 110, 2026-2032.
26. Niell,H.B. et al. (1987) Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer Chemother. Pharmacol., 19, 47-52.
27. Patterson,A.L. et al (2000) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology, 56, 232-235.
28. Wheeland,R.G. (2005) The pitfalls of treating all actinic keratoses as squamous cell carcinomas. Semin. Cutan. Med. Surg., 24, 152-154.
29. Ackerman,A.B. et al. (2006) Solar (actinic) keratosis is squamous cell carcinoma. Br. J. Dermatol., 155, 9-22.
30. Roewert-Huber,J. et al. (2007) Pathology and pathobiology of actinic (solar) keratosis-an update. Br. J. Dermatol., 157 (suppl. 2), 18-20.
31. Digiovanni,J. (1992) Multistage carcinogenesis in mouse skin. Pharmacol. Ther., 54, 63-128.
32. Chuang,L.F. et al. (1992) Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin14-valerate (AD 32). Biochem. Pharmacol., 43, 865-872.
33. Liskamp,R.M. et al. (1985) Cellular uptake and localization of fluorescent derivatives of phorbol ester tumor promoters. Biochem. Biophys. Res. Commun., 131, 920-927.
34. Kazi,J.U. et al. (2007) Isoform-specific translocation of PKC isoforms in NIH3T3 cells by TPA. Biochem. Biophys. Res. Commun., 364, 231-237.
35. Roaten,J.B. et al. (2001) Molecular models of N-benzyladriamycin-14valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta. J. Med. Chem., 44, 1028-1034.
36. Denning,M.F. et al. (1995) Cholesterol sulfate activates multiple protein kinase C isoenzymes and induces granular cell differentiation in cultured murine keratinocytes. Cell Growth Differ., 6, 1619-1626.
37. Geiges,D. et al. (1995) Loss of protein kinase C delta from human HaCaT keratinocytes upon ras transfection is mediated by TGF alpha. Exp. Cell Res., 219, 299-303.
38. Papp,H. et al. (2004) Opposite roles of protein kinase C isoforms in proliferation, differentiation, apoptosis, and tumorigenicity of human HaCaT keratinocytes. Cell. Mol. Life Sci., 61, 1095-1105.
39. Greenberg,R.E. et al. (1997) Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology, 49, 471-475.
40. Zirvi,K.A. et al. (1985) Embryotoxic effects of doxorubicin and N-trifluoroacetyladriamycin-14-valerate (AD-32). Teratology, 31, 247-252.
41. Katiyar,S.K. et al. (2005) Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol. Cancer Ther., 4, 207-216.
42. Ouhtit,A. et al. (2000) Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am. J. Pathol., 156, 201-207.
43. Lehman,T.A. et al. (1993) p53 mutations in human immortalized epithelial cell lines. Carcinogenesis, 14, 833-839.
44. Hofmann,P.A. et al. (2007) N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation. J. Pharmacol. Exp. Ther., 323, 658-664.
45. Ganapathi,R. et al. (1989) N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. Br. J. Cancer, 60, 819-826.
46. He,Y. et al. (2005) N-benzyladriamycin-14-valerate (AD198) induces apoptosis through protein kinase C-delta-induced phosphorylation of phospholipid scramblase 3. Cancer Res., 65, 10016-10023.
47. He,Y. et al. (2007) Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J. Cell. Biochem., 101, 1210-1221.